Mal-PEG8-Phe-Lys-PAB-Exatecan

Cat. No.: HY-148380: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Mal-PEG8-Phe-Lys-PAB-Exatecan (compound 15) is a agent-linker conjugate for ADC, composed of degradable linker Mal-PEG8-Phe-Lys-PAB and toxin molecule Exatecan (HY-13631) composition.

For research use only. We do not sell to patients.

Mal-PEG8-Phe-Lys-PAB-Exatecan Chemical Structure

CAS No. : 2679821-44-2

Size		Stock
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Mal-PEG8-Phe-Lys-PAB-Exatecan:

Other Forms of Mal-PEG8-Phe-Lys-PAB-Exatecan:

Mal-PEG8-Phe-Lys-PAB-Exatecan TFA In-stock

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Drug-Linker Conjugates for ADC Isoform Specific Products:

View All Isoforms

Auristatin Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

Biological Activity
Purity & Documentation
References
Customer Review

Description

Mal-PEG8-Phe-Lys-PAB-Exatecan (compound 15) is a agent-linker conjugate for ADC, composed of degradable linker Mal-PEG8-Phe-Lys-PAB and toxin molecule Exatecan (HY-13631) composition^[1].

Molecular Weight

1434.56

Formula

C₇₃H₉₂FN₉O₂₀

CAS No.

2679821-44-2

SMILES

O=C(C=CC1=O)N1CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCC(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](CCCCN)C(NC(C=C3)=CC=C3COC(N[C@@H]4C5=C6C(C(N7C6)=CC([C@](O)(C(OC8)=O)CC)=C8C7=O)=NC9=CC(F)=C(C)C(CC4)=C95)=O)=O)=O)=O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent & Solubility

In Vitro:

DMSO : 180 mg/mL (125.47 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.6971 mL	3.4854 mL	6.9708 mL
5 mM	0.1394 mL	0.6971 mL	1.3942 mL
10 mM	0.0697 mL	0.3485 mL	0.6971 mL

View the Complete Stock Solution Preparation Table

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 4.5 mg/mL (3.14 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 4.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (45.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 4.5 mg/mL (3.14 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 4.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (45.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 4.5 mg/mL (3.14 mM); Clear solution

This protocol yields a clear solution of ≥ 4.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (45.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Manel KRAIEM. Treatment of cancer. Patent WO2021151984A1.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	0.6971 mL	3.4854 mL	6.9708 mL	17.4269 mL
	5 mM	0.1394 mL	0.6971 mL	1.3942 mL	3.4854 mL
	10 mM	0.0697 mL	0.3485 mL	0.6971 mL	1.7427 mL
	15 mM	0.0465 mL	0.2324 mL	0.4647 mL	1.1618 mL
	20 mM	0.0349 mL	0.1743 mL	0.3485 mL	0.8713 mL
	25 mM	0.0279 mL	0.1394 mL	0.2788 mL	0.6971 mL
	30 mM	0.0232 mL	0.1162 mL	0.2324 mL	0.5809 mL
	40 mM	0.0174 mL	0.0871 mL	0.1743 mL	0.4357 mL
	50 mM	0.0139 mL	0.0697 mL	0.1394 mL	0.3485 mL
	60 mM	0.0116 mL	0.0581 mL	0.1162 mL	0.2904 mL
	80 mM	0.0087 mL	0.0436 mL	0.0871 mL	0.2178 mL
	100 mM	0.0070 mL	0.0349 mL	0.0697 mL	0.1743 mL